Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.46 Insider Own16.44% Shs Outstand43.55M Perf Week-1.03%
Market Cap293.96M Forward P/E- EPS next Y-1.20 Insider Trans0.48% Shs Float36.39M Perf Month35.54%
Income-88.33M PEG- EPS next Q-0.29 Inst Own67.97% Short Float0.70% Perf Quarter28.82%
Sales16.93M P/S17.36 EPS this Y43.94% Inst Trans-0.43% Short Ratio1.53 Perf Half Y177.78%
Book/sh3.53 P/B1.91 EPS next Y22.38% ROA-38.67% Short Interest0.25M Perf Year128.81%
Cash/sh4.95 P/C1.36 EPS next 5Y- ROE-61.85% 52W Range1.62 - 7.87 Perf YTD15.78%
Dividend Est.- P/FCF- EPS past 5Y- ROI-35.27% 52W High-14.23% Beta0.84
Dividend TTM- Quick Ratio6.56 Sales past 5Y289.37% Gross Margin67.14% 52W Low316.67% ATR (14)0.54
Dividend Ex-Date- Current Ratio6.56 EPS Y/Y TTM4.25% Oper. Margin-535.94% RSI (14)59.86 Volatility8.36% 9.26%
Employees137 Debt/Eq0.51 Sales Y/Y TTM27.37% Profit Margin-521.63% Recom1.17 Target Price10.80
Option/ShortNo / Yes LT Debt/Eq0.48 EPS Q/Q64.06% Payout- Rel Volume0.85 Prev Close6.71
Sales Surprise-12.67% EPS Surprise46.97% Sales Q/Q15.58% EarningsNov 09 BMO Avg Volume165.14K Price6.75
SMA2010.24% SMA5017.73% SMA20076.23% Trades Volume139,876 Change0.60%
Date Action Analyst Rating Change Price Target Change
Jun-22-23Initiated Wedbush Outperform $8
Feb-28-24 07:00AM
Feb-26-24 07:00AM
Feb-19-24 05:49AM
Feb-14-24 07:00AM
Feb-06-24 07:00AM
07:00AM Loading…
Jan-29-24 07:00AM
Jan-18-24 07:00AM
Jan-04-24 07:00AM
Dec-09-23 12:00PM
Dec-07-23 07:00AM
Dec-06-23 08:50AM
Dec-04-23 04:05PM
Dec-01-23 09:55AM
Nov-30-23 07:00AM
12:00PM Loading…
Nov-27-23 12:00PM
Nov-20-23 08:50AM
Nov-15-23 12:00PM
Nov-09-23 08:25AM
Nov-06-23 07:00AM
Nov-02-23 09:05AM
Oct-12-23 12:00PM
Sep-27-23 09:06AM
Sep-12-23 08:00AM
Sep-05-23 07:00AM
Aug-29-23 07:00AM
Aug-16-23 12:00PM
Aug-10-23 08:25AM
07:00AM Loading…
Jul-13-23 07:25AM
Jun-29-23 07:00AM
Jun-15-23 07:42AM
Jun-06-23 07:00AM
Jun-01-23 04:10PM
May-26-23 12:37AM
May-25-23 04:06PM
May-24-23 04:13PM
May-17-23 04:35PM
May-11-23 07:33AM
May-10-23 08:15AM
May-09-23 01:29PM
May-02-23 04:42PM
Apr-10-23 07:00AM
Mar-31-23 08:00AM
Mar-14-23 07:00AM
Mar-13-23 04:05PM
Mar-10-23 05:12AM
Mar-08-23 07:00AM
Mar-01-23 07:00AM
Feb-21-23 07:00AM
Jan-23-23 07:00AM
Jan-20-23 05:35AM
Jan-05-23 07:00AM
Dec-12-22 07:00AM
Dec-09-22 06:09AM
Dec-01-22 08:00AM
Nov-22-22 07:00AM
Nov-11-22 07:00AM
Nov-09-22 07:00AM
Nov-07-22 07:00AM
Nov-03-22 09:34AM
Oct-05-22 08:33AM
Sep-28-22 09:21AM
Sep-22-22 07:00AM
Sep-12-22 07:00AM
Sep-07-22 07:00AM
Aug-13-22 08:14AM
Aug-12-22 06:08AM
Aug-10-22 07:00AM
Aug-05-22 11:58AM
Aug-03-22 07:00AM
Jul-11-22 07:00AM
Jul-07-22 07:00AM
Jul-06-22 08:28AM
Jun-22-22 07:00AM
Jun-02-22 07:00AM
May-31-22 07:00AM
May-22-22 08:03AM
May-19-22 07:00AM
May-17-22 07:00AM
May-12-22 07:00AM
May-09-22 07:00AM
May-05-22 10:25AM
May-02-22 05:02PM
Apr-11-22 07:00AM
Mar-09-22 07:00AM
Mar-02-22 07:00AM
Feb-18-22 12:39PM
Feb-10-22 07:00AM
Jan-24-22 12:30PM
Jan-10-22 07:00AM
Dec-20-21 01:36PM
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBERICH TIMOTHY JDirectorDec 19Buy4.973171,57567,027Dec 21 05:00 PM
BARBERICH TIMOTHY JDirectorDec 18Buy4.8928,830140,88166,710Dec 21 05:00 PM
Klencke BarbaraDirectorDec 14Buy5.085,00025,40030,000Dec 18 06:01 PM
BARBERICH TIMOTHY JDirectorJun 02Buy2.6337,88099,56437,880Jun 06 07:53 PM
Lynx1 Capital Management LP10% OwnerMay 31Sale2.5225,40063,9525,224,600Jun 02 05:35 PM